Immunological Consequences of JAK Inhibition: Friend or Foe?

JAK2 activation by growth hormone and other cytokines

(2015) Michael J. Waters et al.   BIOCHEMICAL JOURNAL

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects

(2015) C. Carniti et al.   CLINICAL CANCER RESEARCH

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vivotumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity

(2015) Michaela Prchal-Murphy et al.   OncoImmunology

Immunology of Psoriasis

(2014) Michelle A. Lowes et al.   Annual Review of Immunology

JAK inhibitors: a home run for GVHD patients?

(2014) T. Teshima   BLOOD

Expansion of circulating CD56brightnatural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α

(2014) Caroline H. Riley et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Immune Dysregulation in MPN

(2014) Giovanni Barosi   Current Hematologic Malignancy Reports

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

(2013) Satoshi Kubo et al.   ANNALS OF THE RHEUMATIC DISEASES

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

(2013) W.C. Ports et al.   BRITISH JOURNAL OF DERMATOLOGY

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib

(2013) B. S. Wilkins et al.   HAEMATOLOGICA

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

(2013) G Caocci et al.   LEUKEMIA

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

(2013) M Massa et al.   LEUKEMIA

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

(2013) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns

(2013) Wilma Barcellini et al.   LEUKEMIA RESEARCH

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib

(2013) Roger A. Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

(2012) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

(2012) A. Eghtedar et al.   BLOOD

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Ruxolitinib can mask symptoms and signs of necrotizing fasciitis

(2012) G.W.D. Landman et al.   JOURNAL OF INFECTION

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis

(2012) Naresh Punwani et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance

(2012) Vibe Skov et al.   LEUKEMIA RESEARCH

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo

(2011) M. Ishizaki et al.   JOURNAL OF IMMUNOLOGY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Autoimmunity and the risk of myeloproliferative neoplasms

(2010) S. Y. Kristinsson et al.   HAEMATOLOGICA

Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice

(2010) Madhav D. Sharma et al.   IMMUNITY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Loss of Jak2 Selectively Suppresses DC-Mediated Innate Immune Response and Protects Mice from Lethal Dose of LPS-Induced Septic Shock

(2010) Jixin Zhong et al.   PLoS One

Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-  on activation

(2010) A. De Maria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Dendritic cell homeostasis

(2009) M. Merad et al.   BLOOD

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

(2009) C. Fauriat et al.   BLOOD

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD